Case Report
Long-Acting Oral Cariprazine
Bibliographic Data
| ID | 15524868 |
|---|---|
| Authors | Emanuela Dyrmishi (Organizzazione Sociopsichiatrica Cantonale), Marco De Pieri (University of Insubria, corresponding author), Marco Ferrari (0000-0003-2068-8466), Rafael Traber (0000-0002-0737-3147, Organizzazione Sociopsichiatrica Cantonale), Matteo Preve, Luca De Peri (0000-0002-5342-2763, Organizzazione Sociopsichiatrica Cantonale), Emilio Bolla (0000-0003-1515-9295, Organizzazione Sociopsichiatrica Cantonale) |
| Year | 2022 |
| Volume | 13 |
| Pages | 876003-876003 |
| Publication date | 2022-04-27 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2022.876003 |
| PMID | 35573352 |
| OpenAlex | W4285742930 |
| Language | EN |
| Citations received | 1 |
| References cited | 30 |
Reported results support our hypothesis that long half-lives of cariprazine and its metabolites provide an adequate therapeutic response with a two-times a week administration. In selected patients, cariprazine administered as a "oral long-acting" seems effective in treating acute episodes of illness and in sustaining remission, combining advantages of oral and long-acting injectable antipsychotics concerning therapeutic alliance
Agonist · Antipsychotic · Partial agonist · Psychiatry · Psychosis · Receptor · Schizoaffective disorder · Schizophrenia (object-oriented programming · Bipolar Disorder and Treatment · Medicine · Psychology · Schizophrenia research and treatment · Treatment of Major Depression · Internal Medicine
| Citations per year | 0.33 |
|---|---|
| Citation span | 2023 - 2023 (1) |
| Highly cited | No |